Program
Charcoal
Also written as “AST-120”, “charcoal” and “Z7200 with oral activated charcoal”.
Its studies are mostly in Multiple Sclerosis · Renal Insufficiency, Chronic · Asthma · Pouchitis · Hepatic Encephalopathy, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keenova Therapeutics | 70 open or running | phase 3since May 1, 2006 | May 1, 2006 | none ahead |
| Zambon SpA | 20 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
Also a collaborator on its studies: kureha-corporation, Kyntra Bio and toray-industries-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 1, 2006First study: phase 3 study in Inflammatory Bowel DiseasesNew to Keenova TherapeuticsKeenova Therapeutics · NCT00321412 · 191 enrolled · United States, Austria, Belgium and more
- Nov 9, 2007Phase 2 study in Hepatic EncephalopathyKeenova Therapeutics · NCT00558038 · 40 enrolled · United States
- Dec 20, 20074 phase 2 studiesKeenova Therapeutics · NCT00583531, NCT00583128, NCT00583076 and 1 more
- Mar 20, 2009Phase 2 study in Hepatic EncephalopathyKeenova Therapeutics · NCT00867698 · 148 enrolled · United States
- Sep 2, 2014Zambon SpA's first study: phase 1 study in AsthmaNew to Zambon SpAZambon SpA · NCT02237508 · 90 enrolled · United Kingdom
- Dec 14, 2015Phase 1 study in AsthmaZambon SpA · NCT02631941 · 91 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT02631941Asthma · United Kingdom | 1 | Completed | Zambon SpA | Jul 2016 | 91 |
| NCT02237508Asthma · United Kingdom | 1 | Completed | Zambon SpA | Feb 2015 | 90 |
| NCT00867698Hepatic Encephalopathy · United States | 2 | Completed | Keenova Therapeutics | Apr 2010 | 148 |
| NCT00587275Gastroesophageal Reflux · United States | 2 | Terminated | Keenova Therapeutics | Jun 2008 | 4 |
| NCT00583531Pouchitis · United States | 2 | Terminated | Keenova Therapeutics | Dec 2008 | 2 |
| NCT00583128Irritable Bowel Syndrome · United States, Belgium | 2 | Completed | Keenova Therapeutics | May 2010 | 117 |
| NCT00583076Pouchitis · United States | 2 | Completed | Keenova Therapeutics | Mar 2008 | 19 |
| NCT00558038Hepatic Encephalopathy · United States | 2 | Completed | Keenova Therapeutics | Mar 2009 | 40 |
| NCT00321412Inflammatory Bowel Diseases · United States, Austria, Belgium and more | 3 | Completed | Keenova Therapeutics | Mar 2008 | 191 |
How it is read
Names in the registry
- “AST-120”, 10 entries
- “charcoal”, 2 entries
- “Z7200 with oral activated charcoal”, 2 entries
- “Symbicort Turbohaler with oral activated charcoal”, 1 entry
- “Activated Charcoal”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 2 studies
- Renal Insufficiency, Chronic, 2 studies
- Asthma, 2 studies
- Pouchitis, 2 studies
- Hepatic Encephalopathy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.